Neurocrine Biosciences | NBIX - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
AbbVie USD 5.57B 2.9B 2026-03
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Exelixis USD 267.69M 15M 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Incyte USD 343.6M 46.34M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Pfizer USD 5.18B 6.82B 2026-03
Prothena USD -21.58M 15.33M 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Repligen USD 19.11M 2M 2025-12
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03
Xoma USD 15.98M 24.58M 2024-06